Business
ZYUS Life Sciences Provides Update on Clinical Trial Progress and Unit Private Placement
ZYUS Life Sciences Provides Update on Clinical Trial Progress and Unit Private Placement ...
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"\n\n\nZYUS Life Sciences Provides Update on Clinical Trial Progress and Unit Private Placement\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nCanada NewsWire\n\n\nPatient enrollment in ZYUS' Phase 2a UTOPIA-1 trial reaches key milestone\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\nSASKATOON, SK , Dec. 8, 2025 /CNW/ - ZYUS Life Sciences Corporation (the \"Company\") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced a key milestone in its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial, with patient enrollment reaching twenty-five percent.\n\n\n\n\n\n\n\nClinical Trial Update\nZYUS' Phase 2a UTOPIA-1 trial evaluating safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain has reached twenty-five percent enrollment. Enrollment continues across three active clinical sites, with screening and dosing activities progressing as expected. Preliminary safety and efficacy results are anticipated early Q1 of 2026.\n\"We are pleased to have reached twenty-five percent patient enrollment, a significant step that underscores patient interest and the ongoing unmet needs of those experiencing cancer pain\", said Brent Zettl, President and CEO of the Company. \"This milestone marks meaningful progress as the UTOPIA-1 trial continues gathering the data needed to evaluate the potential clinical benefit of Trichomylin® softgel capsules.\"\nFor more information about the Phase 2a UTOPIA-1 trial, please visit clinicaltrials.gov and reference identifier NCT06533657.\nUnit Private Placement Update\nAs disclosed in the Company's news release dated November 7, 2025, ZYUS raised a total of $1,250,000.50 in gross proceeds via a non-brokered private placement, all of which was raised in the first tranche that closed on November 7, 2025. Th...